This week's FierceBiotech is brought to you by VERISTAT.

Trouble viewing? Click here.


VERISTAT
Strategies to Drive Clinical Development Success During COVID-19
The COVID-19 pandemic and subsequent social distancing measures around the world have disrupted the clinical trial landscape, bringing an overwhelming degree of stress, anxiety, and uncertainty to ongoing, new, and COVID-19-related clinical development programs. Regulations and guidelines for clinical trial conduct are rapidly evolving and affecting sponsors who are running or planning new clinical studies. We understand that these changes are disrupting your clinical trials.
As you consider the impact of COVID-19, there are several key strategies to help you maintain momentum, assess your risks, and minimize the delays for ongoing, new, and COVID-19-related trials. Our agile and scientific-minded experts have compiled a guide of critical strategies for clinical development success during the COVID-19 era, which include:
Staying informed of updated, new, and rapidly changing regulations, and working closely with regulatory agencies
Implementing operational changes to continue trials in a more virtual ecosystem while still ensuring patient safety
Understanding how trial conduct changes will affect your trial’s data integrity
Read our guide to learn more.
Read Guide
Veristat
> Contact > www.veristat.com facebook twitter linkedIn

Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.



You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from FierceBiotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400 
Washington, DC 20036